It's either Pfizer because it's main cancer drug is going off patent in a few years or someone who sees potential in a drug not targeting surface antigen markers which is old IP . Cell nucleus penetrative antibodies are the new potential in cancer treatment. Novel and unique we are.
Ann: New PAT-DX3 data demonstrates synthetic lethality, page-25
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.8¢ | 0.7¢ | $23.67K | 2.969M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 13454700 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 250000 | 1 |
View Market Depth
| Last trade - 15.08pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.8¢ |
Change
0.000 ( 14.3 %) |
||||
| Open | High | Low | Volume | ||
| 0.7¢ | 0.8¢ | 0.7¢ | 2027477 | ||
| Last updated 15.57pm 28/05/2024 ? | |||||
| PAB (ASX) Chart |